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Abstract
Background: SOX4 is a developmental transcription factor that is required for differentiation and proliferation in
multiple tissues. SOX4 is overexpressed in many human malignancies, but the precise role of SOX4 in cancer
progression is still not well understood. Thus, the identification of additional SOX4 binding partners is essential for
elucidating the mechanism of SOX4-mediated effects in cancer progression.
Results: Here, we have adapted a one-step affinity purification method that enables rapid purification of SOX4
complexes via intracellular biotinylation of the amino-terminus of SOX4 to perform large-scale proteomics analysis.
We have discovered that junction plakoglobin (JUP) interacts with SOX4 in both the cytosol and the nucleus and
the interaction between SOX4 and plakoglobin is significantly increased when prostate and breast cancer cells are
stimulated with WNT3A. Interactions between SOX4 and plakoglobin were further enhanced by the nuclear export
inhibitor leptomycin B (LMB), suggesting that plakoglobin promotes nuclear export of SOX4. The SOX4-plakoglobin
complex affected the expression of Wnt pathway target genes and SOX4 downstream targets, such as AXIN2,
DICER1, and DHX9. In addition, SOX4 DNA binding activity to the promoters of DICER1, AXIN2, DHX9 and SOX4 itself
was reduced by conditions that promote SOX4-plakoglobin complex formation. Conditions that enhanced SOX4-
plakoglobin interactions resulted in reduced transcriptional activity of b-catenin luciferase reporters.
Conclusions: These data suggest that this newly identified interaction between SOX4 and plakoglobin is inhibitory
and provides new insights into the role of SOX4 in key pathways in cell proliferation, development, and cancer
progression.
Background
The sex-determining region Y (SRY) box, or SOX,
family consists of 20 highly conserved transcription fac-
tors in humans that play important roles in development
[1]. SOX4 is a 47-kDa protein that is encoded by a sin-
gle exon gene and contains a conserved signature
sequence in the high-mobility group (HMG) DNA-bind-
ing domain (DBD) related to the TCF/LEF family of
transcription factors. The key effector of the canonical
Wnt pathway, b-catenin, forms complexes with TCF/
LEF HMG box factors and stimulates the transcription
of Wnt downstream targets. Many studies have shown
that b-catenin is regulated at several levels in cancer
progression, but less is known about the regulation of
the TCF/LEF transcription factor family. Structurally
related to TCF/LEFs, several members of the SOX
family, SOX17, SOX7, SOX9, and SOX4 have been
implicated in regulating b-catenin activity [2-4]. Gain-
and loss-of-function analyses have demonstrated that
SOX17 and SOX7 proteins antagonize the Wnt pathway
by competing with TCFs for b-catenin binding while
SOX4 may function to stabilize b-catenin protein to
help activate expression of target genes and promote
cellular proliferation [5]. Although these findings have
implicated how SOX proteins regulate the transcrip-
tional output of Wnt pathway, the precise role of SOX4
in the Wnt pathway remains unclear.
In humans, tight regulation of the levels of transcrip-
tional factors is crucial to maintain tissue homoeostasis
and many have been found to be oncogenic when their
expression is deregulated or when their activity is func-
tionally altered [6]. For example, SOX4 is overexpressed
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any medium, provided the original work is properly cited.in several cancers, such as bladder cancer, in which it is
5-fold upregulated compared with normal tissues [7].
SOX4 is also upregulated at the mRNA and protein
level in prostate cancer and this upregulation is corre-
lated with higher Gleason score or tumor grade [8]. In
addition, SOX4 is overexpressed in leukemias, melano-
mas, glioblastomas, medulloblastomas [9], and lung can-
cer [10]. SOX4 is also overexpressed in endometrial
cancer through methylation-mediated silencing of miR-
129-2 [11]. Consistent with the concept that SOX4 is an
oncogene, three independent studies searching for onco-
genes have found SOX4 to be one of the most common
retroviral integration sites, resulting in increased mRNA
[12-14].
Junction plakoglobin (JUP), also known as g-catenin, is
a major component of the submembrane of adherens
junctions and desmosomes in mammalian cells [15]. It
is closely related to the Drosophila segment polarity
gene armadillo, which has a role in the transduction of
transmembrane signals that regulate cell fate [16,17].
Plakoglobin shares more than 76% homology with b-
catenin, contains a central armadillo repeat domain
flanked by the carboxyl and amino terminal domains,
and functions in cell-cell junctions, along with b-catenin
and a-catenin when coupled with cadherins [18]. While
it is known that b-catenin is essential in the Wnt signal-
ing cascade, plakoglobin also binds to TCF/LEF factors,
and has lower TCF/LEF-dependent transcriptional activ-
ity compared to b-catenin when endogenous b-catenin
is depleted [19,20].
Mass spectrometry is a highly sensitive technique that
enables the rapid identification of proteins and also pro-
tein-protein interactions from a variety of biological
samples. When combined with affinity purification,
whole or targeted protein interaction networks can be
elucidated [21]. To investigate the cellular functions of
SOX4, we have developed a one-step affinity purification
method that enables rapid purification of SOX4 com-
plexes in LNCaP cells, a prostate cancer cell line. Here,
in this study, we identified proteins that interact with
SOX4 in LNCaP cells by liquid chromatography-tandem
mass spectrometry (LC-MS/MS), including plakoglobin.
This novel interaction between SOX4 and plakoglobin
may provide insights into the role of SOX4 in key path-
ways in cell proliferation, development, and cancer
progression.
Methods
Reagents and cell culture
LNCaP, PC3M, and MDA-MB-231 cells were cultured
as described [22] by American Type Culture Collection
except using T-medium (Invitrogen) for LNCaP cells.
HA-tagged SOX4 was cloned into pHR-UBQ-IRES-
eYFP-ΔU3 lentiviral vector (gift from Dr. Hihn Ly,
Emory University), and stable cells were isolated, as pre-
viously described [23]. Recombinant WNT3A was pur-
chased from R & D Systems (5036-WNP) and
reconstituted in 0.1% BSA/PBS prior to use. Nuclear
export inhinbitor leptomycin b (LMB) was purchased
from Sigma (L2913). Cells were treated for 24 hrs with
100 ng/ml WNT3A, 20 μM LMB, or both unless other-
wise noted.
Biotinlyated HA-tagged SOX4 expression construct
The pREP4-BLRPwt-IRES-BirA-XL9 plasmid was a gift
from Dr. Jeremy Boss (Emory University). The
pcDNA3.1-HisA-HASOX4 was constructed as described
[8]. To generate pREP4-BLRPwt-HASOX4-IRES-BirA-
XL9, HA-tagged SOX4 from pcDNA3.1-HisA-HASOX4
was excised at KpnI and XbaI sites and overhangs were
filled in with Klenow fragment. Filled-in HA-SOX4 was
then blunt ligated into the filled-in NotI site of pREP4-
BLRPwt-IRES-BirA-XL9.
Purification of biotinlyated HA-tagged SOX4
The pREP4-BLRPwt-HASOX4-IRES-BirA-XL9 and con-
trol empty vector were transfected into two 90% conflu-
ent 100 mm dishes of LNCaP cells respectively. Forty-
eight hours post-transfection, the plates were then
placed on ice and the cells were washed twice with ice-
cold PBS, and lysed in 1 ml/plate with ice-cold IP lysis
buffer (0.137 M NaCl, 0.02 M Tris pH8.0, 10% glycerol,
1% NP-40) supplemented with protease inhibitors, and
harvested by scraping. Biotinlyated HA-tagged SOX4
complexes were purified by incubating with 50 ul slurry
of Dynabeads
® M280 Streptavidin (Invitrogen) at 4°C
for 2 hrs. The beads ware washed 3 times with IP lysis
buffer and eluted by boiling in Laemmli sample buffer.
Sample preparation for mass spectrometry
Five percent of the proteins resulting from the purifica-
tion were subject to 4-15% gradient SDS-PAGE and sil-
ver staining to analyze sample purity. The rest of the
purified proteins were subjected to 4-15% gradient SDS-
P A G Ea n dc o n c e n t r a t e do nav e r ys h o r td i s t a n c e( ~ 2
mm long), and the protein in those bands were excised
for in-gel digestion and Liquid chromatography coupled
with tandem mass spectrometry based on an optimized
protocol [21].
Co-immunoprecipitation and Western blot
Cells were washed twice with ice-cold PBS, lysed in 1
ml/plate with ice-cold IP lysis buffer supplemented with
protease inhibitors, and harvested by scraping. The
whole cell lysates were pre-cleared and then incubated
with 25 ul slurry of Dynabeads
® M280 Streptavidin or
protein G (Invitrogen) at 4°C for 2 hrs. The beads were
washed 3 times with IP lysis buffer and eluted by boiling
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Western blots were performed as previously described
[23]. Antibodies to plakoglobin (13-8500, Invitrogen)
and hemagglutinin (HA12CA5) were used in immuno-
precipitations (IPs). Antibodies to plakoglobin (610253,
BD Biosciences), SOX4 (LS-B3520, LifeSpan Bios-
ciences), b-actin (3700S, Cell Signaling), and HA 16B12
(AFC-101P-1000, Covance Research Products) were
used in Western blot.
Confocal microscopy
Sub-confluent LNCaP HASOX4 stable cells were grown
on glass cover slips, and serum starved for 24 hrs with
0.5% FBS (fetal bovine serum) T-Medium before treating
with 100 ng/ml WNT3A, 20 μM LMB, or both for
another 24 hrs. Cells were washed three times with
Hank’s Balanced Salt Solution (HBSS
+)a n df i x e dw i t h
3.7% paraformaldehyde for 20 min at room temperature.
Cells were permeablized with 100% ethanol for 20 min at
-20°C and blocked in 3% BSA in HBSS
+ for 1hr. anti-HA
16B12 (1:500 dilution) and plakoglobin antibodies (1:50
dilution) (sc-H80, Santa Cruz Biotechnology) were used
as primary antibodies and were diluted in blocking buffer
and incubated for 1 hr. Then cells were washed in HBSS
+
and incubated in fluorescence-labeled secondary antibo-
dies for 1hr at room temperature. Cells were washed in
HBSS
+ and then stained with Topro (T3605, Invitrogen)
for 5 min at room temperature. Labeled cells were then
washed in HBSS
+ and mounted in p-phenylene diamine
antifade agent. Confocal fluorescence images were cap-
tured using a laser-scanning microscope.
Cell fractionation into nuclear and cytosolic lysates
One 100-mm dish of LNCaP HASOX4 stable cells was
grown to 80-90% confluency and serum starved for 24
hrs with 0.5% FBS T-Medium before treating with 100
ng/ml WNT3A, 20 μM LMB, or both for another 24
hrs. Crude subcellular fractionation was performed as
previously described using digitonin, NP40, and RIPA
lysis methods [24].
Quantitative real-time PCR
Ninety-percent confluent cells were harvested using the
RNeasy kit (Qiagen), and reverse transcription was per-
formed using iScript cDNA Synthesis Kit (Bio-Rad
Laboratories). Quantitative real-time PCR (qPCR) was
performed using iQ SYBR Green Supermix (Bio-Rad
Laboratories) on a Bio-Rad iCycler using 18s or b-actin
as a control, and data were analyzed using the δCt
method [25].
Chromatin immunoprecipitation (ChIP) assay
One 100-mm dish of LNCaP HASOX4 stable cells was
grown to 80-90% confluency. Cells were fixed with 1%
formaldehyde, then lysed, and sonicated as described [26].
Sonicated chromatin was precleared and then immuno-
precipitated with 4 μg of anti-HA 12CA5 ascites or mouse
IgG overnight and immunoprecipitated by Dynabeads
®
Protein G (10004D, Invitrogen) for 2 hrs at 4°C. Beads
were washed and eluted as described [26]. ChIP DNA was
purified and then subjected to PCR amplification.
Luciferase reporter assay
Cells grown in twelve-well tissue culture plates were
transfected with 0.5 μg of either TOP-flash or FOP-flash
with 0.04 μg of TK-Renilla control vector (Promega). At
6 hrs post-transfection, cells were placed in 0.5% FBS
medium for recovery and serum starvation. At 24 hrs
post-transfection, cells were treated with WNT3A and
LMB, or both. Reporter gene activity was measured in a
TD-20/20 luminometer (Turner Design) with the DLR
Luciferase Assay System (Promega) after 48 hrs and was
normalized for transfection efficiency by measuring
Renilla luciferase activity.
siRNA transfection
The siRNA sequence for plakoglobin AGTCGGC-
CATTGTGCATCT was targeted at the 5’ end of the
gene lacking of homology with other catenin members
[27] (Dharmacon RNA Technologies). LNCaP HASOX4
cells were transfected using Lipofectamine 2000 (Invitro-
gen) with plakoglobin or scramble siRNAs at final con-
centration of 200 nM. At 6 hrs post-transfection, cells
were placed in 0.5% FBS medium for recovery and
serum starvation. At 24 hrs post-transfection, cells were
treated with WNT3A, LMB, or both for Western blot
analysis or chromatin immunoprecipitation assay.
Results
Identification of proteins that interact with SOX4
To identify proteins that stably interact with SOX4, we
developed a one-step affinity purification method that
allows for rapid purification of SOX4 complexes. The
pREP4-BLRPwt-IRES-BirA-XL9 plasmid contains the birA
gene of E. coli that encodes a biotin holoenzyme synthe-
tase [28]. We cloned the human SOX4 gene into this vec-
tor to generate an amino-terminal fusion to a BirA
recognition sequence to produce transiently expressed,
intracellularly biotinylated SOX4 protein in LNCaP pros-
tate cancer cells, and purified SOX4 complexes with strep-
tavidin-linked magnetic beads to perform large scale
proteomics analysis. Protein quantity and purity were
checked by SDS-PAGE analysis and silver staining prior to
mass spectrometry analysis (Figure 1A).
Plakoglobin interacts with SOX4
LC-MS/MS analysis identified junction plakoglobin (JUP)
as a SOX4 binding protein via two trypsinized fragments
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(Figure 1B). To confirm this interaction, we first repeated
the transient transfection of the pREP4-BLRPwt-IRES-
BirA-XL9-HASOX4 or vector control plasmid into
LNCaP cells, and performed streptavidin-magnetic bead
based purification followed by anti-plakoglobin (JUP)
immunoblotting. As expected, the result of the immuno-
precipitation (IP) and western blot validated the interac-
tion between SOX4 and plakoglobin (Figure 1C).
Furthermore, we performed a reverse-IP immunoprecipi-
tating endogenous plakoglobin and probing for transfected
HA-SOX4 (Figure 1D) and endogenous SOX4 in untrans-
fected LNCaP cells (Figure 1E). To determine that the
interactions were not cell-line specific or DNA-dependent,
we repeated the immunoprecipitations in primary human
keratinocytes, MDA-MB-231 breast cancer cells, and
PC3M prostate cancer cells (Figure 1F-I) following DNase
I digestion of whole cell lysates. Taken together, these data
demonstrate that SOX4 directly interacts with plakoglobin
and that plakoglobin is a novel SOX4 binding partner.
Interaction between SOX4 and plakoglobin in the nucleus
responds to Wnt signaling
When plakoglobin is present in desmosomes, it interacts
with desmoglein and desmocollin, and when in adherens
junctions it interacts with E-cadherin in the cytoplasmic
component [15]. Recently, additional evidence has sug-
gested that plakoglobin contributes a low level of tran-
scriptional activity to the Wnt signal transduction
cascade in the nucleus [19,20]. Although, it has been
confirmed that SOX4 modulates Wnt signaling via
interaction with b-catenin [5,23], the role of plakoglobin
in Wnt signaling is still debated. To investigate where
and under what conditions SOX4 and plakoglobin inter-
act with each other, we used confocal microscopy to
determine whether we could observe subcellular co-
localization of HA-SOX4 and plakoglobin (Figure 2).
After treatment of PC3M cells that stably-expressed
HA-SOX4 with recombinant human WNT3A, we
observed that the interaction between HA-SOX4 and
plakoglobin was slightly increased in the nucleus. In
contrast, this was not observed in the non-transfected
adjacent cells. We observed the same phenomenon in
the LNCaP-HA-SOX4 stable cell line (Additional file 1
Figure S1). Furthermore, when we treated with nuclear
export inhibitor, leptomycin b (LMB) to inhibit nuclear
export of SOX4 and plakoglobin, the co-localization was
significantly increased compared to treating the cells
with either WNT3A or LMB alone (Figure 2). To con-
firm these enhanced interactions, we performed co-
Figure 1 Plakoglobin binds to SOX4 in LNCaP cells. A. Whole cell lysates prepared from LNCaP cells transfected with pREP4-BLRPwt-HASOX4-IRES-
BirA-XL9 or vector only were purified using an streptavidin-magnetic beads, and affinity-purified Vector- and SOX4-complexes were visualized by silver
staining. SOX4 protein is indicated by an arrow. The molecular weight markers are as shown on the left. B. Amino acid sequence of plakoglobin with
trypsinized peptides from LC-MS/MS analysis indicated in bold and underlined. C, pREP4-BLRPwt-HASOX4-IRES-BirA-XL9 and vector control transfected
LNCaP cells. SOX4-associated plakoglobin were analyzed by Western blot with antibodies indicated. Equivalent amounts of the Vector-purified
fractions were used to confirm specificity. 5% of transfected LNCaP whole cell lysate was used as Input. D, endogenous plakoglobin IPs were analyzed
for transfected SOX4 by Western blot with anti-HA 16B12 mAb. E, endogenous plakoglobin IPs were analyzed for endogenous SOX4 in untransfected
LNCaP cells. F, G, endogenous plakoglobin IPs were analyzed for endogenous SOX4 in primary human keratinocytes and breast cancer cell line, MDA-
MB-231, respectively. H, I, HASOX4 IPs were analyzed for endogenous plakoglobin in stably-expressed SOX4 PC3M and LNCaP cell lines. F-I, whole cell
lysates were harvested and treated with DNase I for 1 hr at room temperature prior to immunoprecipitation.
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ditions in LNCaP-HA-SOX4 cells (Figure 3A). The
interaction in the whole cell lysate was quantified and
significantly increased when we treated with WNT3A
and LMB together (Figure 3B). In addition, to determine
that SOX4 and plakoglobin interact in the nucleus, we
prepared cytosolic and nuclear fractions to confirm the
subcellular interaction (Figure 3C). Immunoblots against
AKT and nuclear lamin were used as controls to
demonstrate the purity of the nuclear and cytosolic frac-
tions (Figure 3C). The quantitative results showed that
the interaction in the nuclear but not cytosolic fraction
was significantly increased in response to the WNT3A
and LMB treatment (Figure 3D). These results show
that SOX4 and plakoglobin physically interact in the
nucleus of LNCaP cells.
Figure 2 Wnt signaling induces nuclear colocalization of SOX4 and plakoglobin. Subcellular localization of plakoglobin and SOX4 were
examined by confocal microscopy. PC3M HASOX4 stable cell line was treated with 100 ng/ml human recombinant WNT3A or 20 μM leptomycin
b (LMB), or both WNT3A+LMB for 24 hr. The fields shown were visualized independently by confocal microscopy at the appropriate wavelength
for plakoglobin (488) and SOX4 (543), and Topro (633) respectively, and then the three images were overlaid (Merge). Strong nuclear localization
of plakoglobin was observed in the WNT3A+LMB treated cells that expressed HASOX4. Representative fields from these independent repeated
experiments are shown. Plakoglobin localizes to the nucleus following WNT3A treatment, and this effect is strongly enhanced by LMB co-
treatment, suggesting shuttling of plakoglobin into and out of the nucleus following WNT3A stimulation. Note that plakoglobin nuclear
localization is much stronger in cells expressing HASOX4, suggesting SOX4 may facilitate plakoglobin nuclear import.
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SOX4-plakoglobin interaction
To address the functional consequences of modulation
of SOX4 transcriptional activity by the SOX4-plakoglo-
bin complex, we tested expression of several genes
including the Wnt target gene AXIN2 [29], as well as
SOX4 targets DICER1 and DHX9 [23]. To characterize
if SOX4 DNA binding activity is changed by Wnt-
induced interaction with plakoglobin, we performed
ChIP assays for AXIN2, DICER1, DHX9, and SOX4 (Fig-
u r e4 A ,B ) .C o m p a r e dt ou n t r e a t e dL N C a PH A S O X 4
cells, the binding of SOX4 to AXIN2, DICER1,a n d
DHX9 promoters was increased after Wnt signaling was
induced. However, SOX4 binding was decreased after
treatment with both WNT3A and LMB. This difference
indicates that increasing the interaction between SOX4
and plakoglobin could inhibit SOX4 binding activity to
downstream targets and may inhibit SOX4 transcrip-
tional activity. Quantitative realtime-PCR (qPCR) analy-
sis of the LNCaP SOX4 stable cell line showed
reductions in AXIN2, SOX4, and DHX9 upon co-treat-
ment with WNT3A and LMB (Figure 4C). To determine
Figure 3 Interaction between SOX4 and plakoglobin is affected by Wnt3A signaling. A. LNCaP HASOX4 stable cell lines were treated with
vehicle, Wnt3A, LMB, or Wnt3A + LMB and anti-HA immunoprecipitations were immunoblotted for the presence of plakoglobin. B, Quantitative
analysis of co-IP and Western blots from panel A using the Odyssey
® Infrared Imaging System (Li-Cor Bioscience). Fold changes were calculated
as the ratio of immunoprecipitated plakoglobin to SOX4 relative to the vehicle control panel (untreat). (n = 3, independent biological replicates
performed on separate days; error bars represent SEM; *, p < 0.05; **, p < 0.01 for a one-sided paired t-test) C. (Upper) LNCaP HASOX4 stable cell
lines were treated with vehicle, WNT3A, LMB, or WNT3A + LMB and anti-HA immunoprecipitations were performed using separate cytosolic and
nuclear fractions. (Lower) Anti-AKT and anti-Lamin A antibodies were used as controls to examine markers of cytosolic and nuclear fractions,
respectively, to confirm the purity of each fraction. D. Quantitative analysis of co-IP and Western blots from panel C.
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treatment were dependent on plakoglobin, we targeted
plakoglobin by siRNA to determine whether reduced
plakoglobin levels could rescue the effects we observed
on SOX4 binding to target promoters. Transfection of
LNCaP HA-SOX4 cells with plakoglobin siRNA or
scrambled control siRNA resulted in approximately 50%
knockdown of endogenous plakoglobin protein levels
(Figure 4D). Furthermore, plakoglobin siRNA partially
rescued SOX4 binding to target promoters by ChIP
assay in the presence of WNT3A and LMB, while
scrambled siRNA had no effect (Figure 4E). These data
suggest that SOX4-plakoglobin interactions may inter-
fere with SOX4-mediated transcription in response to
Wnt signaling due to reduced promoter occupancy.
SOX4-plakoglobin complex modulates b-catenin-mediated
transcriptional activity
To evaluate whether SOX4-plakoglobin complex affects
the transcriptional activity of b-catenin, we performed
luciferase reporter assays with T cell factor (TCF) repor-
ter plasmids containing wild type TCF binding sites
Figure 4 SOX4 transcriptional activity is modulated by Wnt-induced interaction with plakoglobin. A. ChIP assay of HA-SOX4 bound to
the predicted SOX4-binding sites on DICER1, SOX4, DHX9, and AXIN2 promoters. GAPDH is shown as a negative control. B. Quantitative results of
ChIP by realtime-PCR. SOX4 promoter occupancy is increased with Wnt treatment, but is strongly reduced by combined WNT3A+LMB treatment.
(n = 4; error bars represent SEM; *, p < 0.05 for a one-sided paired t-test) C. SOX4 targets and Wnt downstream genes are inhibited after Wnt
induction and LMB treatment. Realtime-PCR expression analysis of SOX4 direct targets and Wnt signaling downstream genes after 24 hrs of
WNT3A and LMB treatment. D. siRNA directed against plakoglobin downregulates protein expression in LNCaP HA-SOX4 cell lines. Cells were
harvested 48-hr post-transfection and Western blot were probed with anti-plakoglobin and anti-b-actin antibodies in the presence or absence of
WNT3A treatment. E. Quantitative ChIP-qPCR assay of HA-SOX4 following plakoglobin knockdown. HA-SOX4 promoter occupancy is strongly
reduced by combined WNT3A and LMB treatment but is partially restored when plakoglobin is knocked down by siRNA treatment. Control
scrambled siRNA had no effect (n = 3; error bars represent SEM; *, p < 0.05 for a one-sided paired t-test).
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[30] (Figure 5A). As expected, the TCF/b-catenin luci-
ferase reporter was significantly increased after we
induced Wnt signaling with recombinant WNT3A when
compared to untreated cells. In contrast, co-treatment
with WNT3A and LMB, strongly inhibited increases in
luciferase activity back to baseline unstimulated levels,
suggesting that WNT3A+ LMB-induced SOX4-plako-
globin complexes could compete with and inhibit the
transcriptional activity of b-catenin. In addition, we per-
formed anti-b-catenin ChIP assays on the AXIN2, c-
Myc,a n dDKK1 promoters, and observed that occu-
pancy of these promoters was stimulated by WNT3A,
but that stimulation was inhibited by co-treatment with
WNT3A and LMB (Figure 5B). These results suggest
that b-catenin activity was affected by the SOX4-
plakoglobin complex and that plakoglobin may compete
with b-catenin binding to SOX4 and/or TCF/LEF in the
nucleus.
Discussion
While SOX4 expression is elevated in many malignan-
cies and is tightly correlated with prostate cancer tumor
grade, little is known of the mechanism by which SOX4
affects the progression of prostate cancer. Using LC-
MS/MS proteomic analysis, we identified a novel SOX4
binding protein, junction plakoglobin, in LNCaP pros-
tate cancer cells. We observed a physical association
between SOX4 and plakoglobin with both epitope-
tagged and endogenous SOX4. Although the interac-
tions of SOX4 with plakoglobin were enhanced by co-
treatment of WNT3A and LMB, we could detect this
interaction using four different untransfected and unsti-
mulated cell types (Figure 1F-I) treated with DNase I. In
addition, confocal microscopy and co-immunoprecipita-
tion demonstrated co-localization of SOX4 and plako-
globin in the nucleus when Wnt signaling was induced.
ChIP assays showed the SOX4-plakoglobin complex
affected SOX4 DNA binding activity to the AXIN2,
DICER1,a n dDHX9 promoters that are Wnt signaling
downstream genes and SOX4-associated targets. In
addition, mRNA expression changes were detected in
AXIN2, DICER1,a n dDHX9 by realtime-PCR. These
data suggest that the SOX4-plakoglobin complex may
inhibit Wnt signaling. Indeed, conditions that induced
the increased interaction between SOX4 and plakoglo-
bin caused b-catenin TOP-FLASH transcriptional activ-
ity to be downregulated and reduced occupancy of the
c-Myc promoter by b-catenin.
It is known that SOX4 can directly interact with b-
catenin to enhance Wnt signaling [5,23], but mechanis-
tic data remain very limited. We found that SOX4 inter-
acts with plakoglobin in a WNT3A-dependent manner
in our experimental cancer model. Our model not only
supports the hypothesis that SOX4 may stabilize b-cate-
nin [5], but also suggests a model in which SOX4 can
modulate Wnt signaling by binding either b-catenin or
plakoglobin (Figure 6). In this model, transcriptional
responses to Wnt signalinga r ei n c r e a s e db yS O X 4 - b-
catenin interactions, and subsequently reduced by
SOX4-plakoglobin interactions that facilitate nuclear
export of SOX4. However, when nuclear export is inhib-
ited, plakoglobin competes with b-catenin for binding to
SOX4 and TCF/LEF factors, downregulating Wnt-
responsive transcription and reducing SOX4-DNA bind-
ing. This model is supported by the observation that
combination treatment with WNT3A and LMB
enhanced SOX4-plakoglobin interactions, reduced TCF/
b-catenin TOP-FLASH transcription, reduced SOX4-
DNA binding and b-catenin DNA binding in ChIP
Figure 5 Wnt signaling is downregulated by SOX4-plakoglobin
complex. A. Luciferase assay of LNCaP HASOX4 stable cell line co-
transfected with 40 ng of TK-Renilla with either 500 ng of TOP-flash
or FOP-flash plasmids. Luciferase activity was increased after Wnt
inducement, but decreased in combined WNT3A+LMB treatment. (n
= 3; error bars represent SEM; *, p < 0.05 for a one-sided paired t-
test) B. Quantitative results of ChIP of b-catenin by realtime-PCR. b-
catenin promoter occupancies of Wnt downstream targets, AXIN2, c-
MYC, and DKK1, were increased with Wnt treatment, but is strongly
reduced by combined WNT3A+LMB treatment. (n = 3; error bars
represent SEM; *, p < 0.05; **, p < 0.01 for a one-sided paired t-test)
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targets (Figures 4 and 5). Consistent with our model,
plakoglobin shows little transcriptional activity com-
pared to b-catenin in cell lines that lack b-catenin [19].
Our confocal data show that plakoglobin nuclear loca-
lization is strongly enhanced by LMB co-treatment, sug-
gesting shuttling of plakoglobin into and out of the
nucleus following WNT3A stimulation. Although LMB
is an artificial stimulus, others have shown that plako-
globin overexpression can lead to nuclear localization
[31,32], and plakoglobin is overexpressed [33] and
amplified [34] in several types of cancer. Moreover, pla-
koglobin nuclear localization was much stronger in cells
expressing HASOX4, suggesting cytoplasmic SOX4 may
facilitate plakoglobin nuclear import. Thus, SOX4 may
induce nuclear import of plakoglobin in response to
WNT3A while plakoglobin destabilizes SOX4 from
DNA binding, facilitating nuclear export of SOX4. It is
as yet unclear what signals or modifications might tip
the balance between nuclear import and export of pla-
koglobin-SOX4 complexes, or whether shuttling might
be constitutive.
The role of plakoglobin during cancer progression is
still controversial. When plakoglobin is overexpressed, it
induces cell migration and mobility in HCT116 cells,
suggesting that plakoglobin may have some oncogenic
effects [31]. In contrast, several reports have demon-
s t r a t e dt h a tp l a k o g l o b i nh a s a tumor-suppressive effect
that inhibits tumor cell growth [27,35]. The tumor sup-
pressive activity of plakoglobin may be via nuclear trans-
location to antogonize b-catenin binding to TCF/LEF
proteins in keratinocytes [36], supporting our model
that plakoglobin competes with SOX4-b-catenin interac-
tions in the nucleus.
Conclusion
In summary, we have demonstrated that SOX4 interacts
with plakoglobin in a Wnt-dependent manner in LNCaP
cells and that this complex may function to inhibit Wnt
signaling. Additional studies will be required to elucidate
the detailed mechanisms by which SOX4-plakoglobin
interactions may affect Wnt signaling, but the role of
the SOX4-plakoglobin complex provides novel insights
into the role of SOX4 in Wnt signaling and prostate
cancer progression.
Additional material
Additional file 1: Figure.S1 Wnt signaling induces nuclear
colocalization of SOX4 and plakoglobin. Subcellular localization of
plakoglobin and SOX4 were examined by confocal microscopy. LNCaP
HASOX4 stable cell line was treated with 100 ng/ml human recombinant
WNT3A or 20 μM leptomycin b (LMB), or both WNT3A+LMB for 24 hr.
The fields shown were visualized independently by confocal microscopy
at the appropriate wavelength for plakoglobin (488) and SOX4 (543), and
Topro (633) respectively, and then the three images were overlaid
(Merge). Strong nuclear localization of plakoglobin was observed in the
WNT3A+LMB treated cells that expressed HASOX4. Representative fields
from these independent repeated experiments are shown. Plakoglobin
localizes to the nucleus following WNT3A treatment, and this effect is
strongly enhanced by LMB co-treatment, suggesting shuttling of
plakoglobin into and out of the nucleus following WNT3A stimulation.
Note that plakoglobin nuclear localization is much stronger in cells
expressing HASOX4, suggesting SOX4 may facilitate plakoglobin nuclear
import.
Figure 6 Model depicting the role of SOX4 and plakoglobin in Wnt signaling regulation. When cells are stimulated with WNT3A, Wnt-
responsive genes are upregulated by nuclear localization of b-catenin and transcriptional activation by the b-catenin-TCF/LEF and b-catenin-
SOX4 complexes. Plakoglobin then shuttles into the nucleus and is exported out of the nucleus with SOX4. When nuclear export is inhibited by
LMB, plakoglobin competes with b-catenin for SOX4 binding, destabilizes SOX4 binding to target promoters, and inhibits transcription of target
genes.
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